Status:
UNKNOWN
Reboxetine Adjuvant Therapy for the Treatment of Schizophrenia
Lead Sponsor:
Abarbanel Mental Health Center
Conditions:
Schizophrenia
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
30 patients will randomly be selected and will be administered either reboxetine or a placebo. changes in cognition and behavior will be assessed by computer tests and scales during a six week study p...
Detailed Description
all participants will be administered panss, sans, esrs, calgary, progesterom, sexual functioning scale, ham-a, covy, hamilton depression scale, and cgi and cgi improved rating on the first visit, as ...
Eligibility Criteria
Inclusion
- schizophrenia all types
- 18\>
Exclusion
- uti
- \>65
- non organic state
- no depression treatment
Key Trial Info
Start Date :
March 1 2006
Trial Type :
INTERVENTIONAL
End Date :
November 1 2006
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00409201
Start Date
March 1 2006
End Date
November 1 2006
Last Update
December 8 2006
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Abarbanel Medical Mental Health Center
Bat Yam, Israel, 59100
2
Abarbanel Medical Mental Health Center
Bat Yam, Israel, 59100